"PrimeC: A Promising Breakthrough in ALS Treatment, Enhancing Survival of Motor Neurons"
NeuroSense Therapeutics' investigational therapy, PrimeC, has shown promising results in a lab study by significantly boosting the survival of patient-derived motor neurons in amyotrophic lateral sclerosis (ALS) to levels similar to healthy controls. PrimeC is a fixed-dose combination of the antibiotic ciprofloxacin and the anti-inflammatory celecoxib, targeting inflammation and other mechanisms that damage motor neurons. The therapy is currently being evaluated in a Phase 2b clinical trial, with results expected later this year.